Amicus Therapeutics Inc. (NASDAQ:FOLD)‘s stock had its “outperform” rating restated by investment analysts at Leerink Swann in a research report issued on Wednesday. They currently have a $15.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $17.00. Leerink Swann’s price objective would indicate a potential upside of 150.84% from the stock’s previous close.

A number of other analysts also recently commented on the company. Cowen and Company reissued an “outperform” rating and issued a $12.00 price objective (down previously from $15.00) on shares of Amicus Therapeutics in a research note on Wednesday. JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a $11.00 target price (down from $12.00) on shares of Amicus Therapeutics in a research report on Wednesday. Robert W. Baird reaffirmed a “hold” rating and set a $7.00 target price (down from $9.00) on shares of Amicus Therapeutics in a research report on Tuesday. Chardan Capital reaffirmed a “buy” rating and set a $16.00 target price (up from $15.00) on shares of Amicus Therapeutics in a research report on Tuesday. Finally, Zacks Investment Research lowered Amicus Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, November 23rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $11.08.

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Amicus Therapeutics (NASDAQ:FOLD) traded down 8.14% during trading on Wednesday, hitting $5.98. The stock had a trading volume of 6,881,240 shares. The firm’s market cap is $851.11 million. The firm’s 50 day moving average is $7.82 and its 200 day moving average is $6.97. Amicus Therapeutics has a 1-year low of $4.98 and a 1-year high of $11.58.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($0.33) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.34) by $0.01. The firm earned $2.10 million during the quarter, compared to the consensus estimate of $1.71 million. On average, analysts anticipate that Amicus Therapeutics will post ($1.38) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This report was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another site, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this report can be read at https://www.thecerbatgem.com/2016/11/30/amicus-therapeutics-inc-fold-receives-outperform-rating-from-leerink-swann.html.

In other Amicus Therapeutics news, CFO William D. Baird III sold 20,500 shares of the business’s stock in a transaction dated Tuesday, September 20th. The stock was sold at an average price of $8.00, for a total value of $164,000.00. Following the transaction, the chief financial officer now owns 56,450 shares in the company, valued at $451,600. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Hung Do sold 25,000 shares of the business’s stock in a transaction dated Tuesday, September 6th. The shares were sold at an average price of $7.00, for a total value of $175,000.00. Following the completion of the transaction, the insider now owns 583,453 shares in the company, valued at approximately $4,084,171. The disclosure for this sale can be found here. Insiders own 3.40% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of FOLD. Dynamic Technology Lab Private Ltd purchased a new position in shares of Amicus Therapeutics during the second quarter worth approximately $108,000. Principal Financial Group Inc. increased its position in shares of Amicus Therapeutics by 10.5% in the second quarter. Principal Financial Group Inc. now owns 22,411 shares of the biopharmaceutical company’s stock worth $122,000 after buying an additional 2,122 shares during the period. BlackRock Inc. increased its position in shares of Amicus Therapeutics by 224.8% in the second quarter. BlackRock Inc. now owns 26,443 shares of the biopharmaceutical company’s stock worth $144,000 after buying an additional 18,301 shares during the period. SG Americas Securities LLC purchased a new position in shares of Amicus Therapeutics during the third quarter worth approximately $151,000. Finally, State Board of Administration of Florida Retirement System increased its stake in Amicus Therapeutics by 36.6% in the second quarter. State Board of Administration of Florida Retirement System now owns 55,248 shares of the biopharmaceutical company’s stock valued at $302,000 after buying an additional 14,810 shares during the period.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).

5 Day Chart for NASDAQ:FOLD

Receive News & Stock Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related stocks with our FREE daily email newsletter.